Navigation Links
Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market
Date:4/7/2008

VIENNA, Austria, April 7 /PRNewswire/ -- A biosimilar product for treating the negative effects that cancer chemotherapy can have on the white blood cells of patients is safe and exhibits an identical pharmacokinetic and pharmacodynamic profile compared to a reference product. This is the result of a clinical phase I trial conducted jointly by the Austrian company Kwizda Pharma GmbH and the Indian manufacturer INTAS Biopharmaceuticals Ltd. (IBPL). Upon completion of an upcoming clinical phase III trial, both companies will lodge an application to get the product approved for the European market. The market launch is planned for early 2010.

Neutropenia - a condition whereby the concentration of neutrophils (a type of white blood cell) in the blood is too low - is a serious side effect of cancer chemotherapy and can prevent the treatment from being successful. Granulocyte colony stimulating factor (G-CSF) is a human protein that can reverse neutropenia by initiating the production of neutrophils. Recombinant forms of the protein have already been approved for the European market. However, due to the high costs that are involved, the relevant authority (EMEA) is encouraging applications for biosimilar products.

Similar & Identical

Working in partnership with IBPL, the first and only biopharmaceutical company in India to comply with EU Good Manufacturing Practice (GMP), Kwizda Pharma has now completed a clinical phase I trial as part of the European application process for a biosimilar form of recombinant G-CSF known as Neukine. Neukine exhibits identical efficacy to the EU-approved reference product. Dr. Helmut Brunar, VP of Research & Business Development at Kwizda Pharma sums up the results of the trial: "Not only was Neukine cleared from the patients' blood plasma just as quickly as the reference, but the number of neutrophils also increased with identical kinetics after treatment. We are very pleased with these results." The study was a single-dose, randomised, double-blind, two-way crossover trial and used an active control. The trial involved 36 patients and was carried out by Prof. Bernd Jilma, MD, of the Medical University of Vienna (Department of Clinical Pharmacology).

The trial confirms data from the Indian market, where Neukine has been approved for therapy since 2004. Mani Iyer, Director IBPL, explains: "Over 3,000 cancer patients have already been treated with Neukine in India. No severe adverse reactions were reported, other than those commonly associated with Filgrastim. We are very confident that our joint clinical trials with Kwizda Pharma will demonstrate the quality of Neukine to the European authorities."

Logistics & Products

IBPL operates an EMEA-certified manufacturing facility in India since March 2007 and is now due to launch its products on the European market. As part of its business strategy, IBPL is working with Kwizda Pharma, which is helping to secure EU approval and will provide support with marketing logistics. Kwizda Pharma (established 1853), which has a well-established clinical background and extensive experience with regulatory procedures, is now offering its expertise to companies that manufacture biosimilar products, particularly those based in India.

Dr. Richard A Kwizda on the future prospects of this approach: "India has an excellent R&D basis and a skilled workforce, which makes its biosimilars attractive products for the European market. Our company supports Indian-based manufacturers of biosimilars to secure approval for the European market in a timely and cost-efficient manner."

About Kwizda GmbH

Kwizda GmbH is a privately owned group of companies and has been operating since 1853 (pharmaceutical division). Kwizda Pharma is a leading Austrian manufacturer and wholesaler of proprietary, in-licensed and third-party pharmaceuticals, OTC drugs and hospital infusions. In 2007, the company recorded sales of approximately EUR 50 million.

About IBPL

INTAS Biopharmaceuticals Limited is one of the fastest growing biopharmaceutical companies in India. As an independent biopharmaceutical company of the INTAS Group, it has carved a niche in the biotechnology sector in the country. The company has fully integrated biopharmaceutical operations with an ultra modern R&D facility and an EU GMP-certified manufacturing facility.

Contacts:

Kwizda Pharma GmbH

Helmut Brunar, Ph.D., M.Sc.

VP Research & Business Development

Effingergasse 21

1160 Wien

Austria

T +43-664-822-57-60

E h.brunar@kwizda.at

W http://www.kwizda.at

IBPL - INTAS Biopharmaceuticals Limited

Plot No. 423/P/A/GIDC

Sarkhej Bavla Highway

Moraiya-382210

Ahmedabad

India

W http://www.intasbiopharma.co.in

Copy Editing & Distribution:

PR&D - Public Relations for Research & Education

Campus Vienna Biocenter 2

1030 Vienna, Austria

T +43-1-505-70-44

E contact@prd.at

W http://www.prd.at


'/>"/>
SOURCE Kwizda Pharma GmbH
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
2. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
3. Increasing Dairy Milk Production with Electrolyzed Drinking Water
4. Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
5. Ception Therapeutics Initiates Phase II/III Clinical Trial for Its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children
6. ATS Medical Announces Initial Clinical Results of Stand-Alone Atrial Fibrillation Procedures Using ATS CryoMaze Product Line
7. On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments
8. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
9. Data Demonstrate that Obagi Medical Products Condition & Enhance Skin Care System is an Effective Complement to Facial Rejuvenation Procedures
10. Surgex(TM) Becomes the First and Only BSCG (Banned Substance Control Group) Certified Product Which is Clinically Proven Effective in Sports Recovery and Performance
11. IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 2016 Wegener Polyangiitis - Pipeline Review, ... ,Wegener Polyangiitis - Pipeline Review, H2 2015, provides ... This report provides comprehensive information on the ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
(Date:2/4/2016)... -- Summary Breast cancer, a malignant neoplasm, is ... cancer in women worldwide, accounting for 16% of all ... of women diagnosed with breast cancer has increased over ... has declined due to earlier diagnosis and better treatment ... the past four decades, especially with increasing usage of ...
(Date:2/4/2016)... Frontier Pharma: Chronic Obstructive Pulmonary Disease ... Chronic Obstructive Pulmonary Disease (COPD) is ... the airways and lungs. Persistent breathing difficulties and ... one of the leading causes of morbidity and ... COPD is linked to cumulative exposure to risk ...
Breaking Medicine Technology:
(Date:2/5/2016)... Dallas, Texas (PRWEB) , ... February 05, 2016 , ... ... to allow users to search for and donate to Give To Cure’s campaign ... is an app that lets users make and share payments through a smart device. ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Dr. Justin Scott ... their 2nd Annual No Cost Dental Day to individuals in need. The event is ... of this No Cost Dental Day is to provide dental care to community members ...
(Date:2/5/2016)... ... February 05, 2016 , ... In sleep, when the defenses of ... A hallmark feature of patients with eating disorders is significant self-criticism, and consequently these ... and obsessions are regarded as maladaptive means for coping with this unease, but also ...
(Date:2/5/2016)... ... ... Calls Blacklist has just been updated by mobile app developer Vlad Lee. The ... known bugs within the app. Calls Blacklist allows its users to only have to ... their device’s battery power or memory. It provides a powerful call blocker that is ...
(Date:2/5/2016)... Robles, CA (PRWEB) , ... February 05, 2016 , ... When one is tired of ... be a lifesaver. There are many reasons to rent a storage unit, but before hastily ... service to many; sometimes you simply need more space. But what one is often not ...
Breaking Medicine News(10 mins):